C3 GLOMERULOPATHY (C3G)
Clinical trials for C3 GLOMERULOPATHY (C3G) explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULOPATHY (C3G) trials appear
Sign up with your email to follow new studies for C3 GLOMERULOPATHY (C3G), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First patients dosed in trial for Ultra-Rare kidney disorder
Disease control Recruiting nowThis is the first time a new drug called CPV-104 is being tested in people. The study aims to see if it is safe and how the body handles it in healthy adults and in patients with C3 glomerulopathy (C3G), a very rare and serious kidney disease. The main goal is to check for side e…
Matched conditions: C3 GLOMERULOPATHY (C3G)
Phase: PHASE1 • Sponsor: eleva GmbH • Aim: Disease control
Last updated Apr 02, 2026 07:11 UTC
-
Last-Hope drug access opens for devastating rare diseases
Disease control AVAILABLEThis program provides access to the investigational drug iptacopan for patients with two rare, serious conditions: C3 glomerulopathy (a kidney disease) and paroxysmal nocturnal hemoglobinuria (a blood disorder). It's for patients who have no other treatment options available and …
Matched conditions: C3 GLOMERULOPATHY (C3G)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC